BI (9/6/2023)

CB Partner Webinar {{webinarsregistrationpage::webinar_title}} true {{webinarsregistrationpage::race_approved_pending}} 1 Credit Hour {{webinarsregistrationpage::hero_image}} {{webinarsregistrationpage::hero_image_self_hosted}} {{webinarsregistrationpage::hero_image_desktop_background_position}} {{webinarsregistrationpage::hero_image_mobile_background_position}} {{webinarsregistrationpage::hero_image_custom_padding}} {{webinarsregistrationpage::hero_image_custom_padding_mobile}} Boehringer Ingelheim {{webinarsregistrationpage::supported_by}} {{webinarsregistrationpage::multiple_speakers}}

This webinar will explore new research in sodium-glucose cotransporter-2 (SGLT2) inhibitors, a mainstay treatment for human diabetics that holds promise for diabetic cats. Join Dr. Ellen Behrend as she discusses a prospective study that included 252 client-owned naïve diabetic (85%) or insulin-treated (15%) cats and revealed velagliflozin to be highly effective as a stand-alone oral solution therapy in feline diabetics, normalizing serum chemical parameters and controlling clinical signs with a low overall incidence of ketoacidosis.

{{webinarsregistrationpage::inside_the_webinar_2}} {{webinarsregistrationpage::inside_the_webinar_3}} The mechanism of action of sodium-glucose cotransporter-2 (SGLT2) inhibitors and their role in treating feline diabetes mellitus The efficacy of velagliflozin, an SGLT2 inhibitor, in diabetic cats with regard to glycemic parameters and clinical signs Adverse effects of velagliflozin in diabetic cats {{webinarsregistrationpage::what_youll_learn_bullet_4}} {{webinarsregistrationpage::what_youll_learn_bullet_5}} {{webinarsregistrationpage::what_youll_learn_bullet_6}} {{webinarsregistrationpage::additional_subhead}} {{webinarsregistrationpage::additional_copy}} In adherence with RACE guidelines, CE certificates can only be distributed to individual registrants under the name used upon registration. Group viewers will not be eligible to receive multiple CE certificates.